Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer

Hyejin Choi; Jiehui Deng; Shuai Li; Tarik Silk; Lauren Dong; Elliott J. Brea; Sean Houghton; David Redmond; Hong Zhong; Jonathan Boiarsky; Esra A. Akbay; Paul D. Smith; Taha Merghoub; Kwok Kin Wong; Jedd D. Wolchok

doi:10.1016/j.celrep.2019.03.066

Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer

Hyejin Choi, Jiehui Deng, Shuai Li, Tarik Silk, Lauren Dong, Elliott J. Brea, Sean Houghton, David Redmond, Hong Zhong, Jonathan Boiarsky, Esra A. Akbay, Paul D. Smith, Taha Merghoub, Kwok Kin Wong, Jedd D. Wolchok

Research output: Contribution to journal › Article › peer-review

46 Scopus citations

Abstract

KRAS mutant non-small-cell lung cancer (NSCLC) remains refractory to targeted therapeutics. Choi et al. show that pulsatile, rather than continuous, treatment with MEK inhibitors can maintain T cell activity better and prolong survival in mice with Kras mutant cancer. This effect is further enhanced when combined with CTLA-4 blockade.

Original language	English (US)
Pages (from-to)	806-819.e5
Journal	Cell Reports
Volume	27
Issue number	3
DOIs	https://doi.org/10.1016/j.celrep.2019.03.066
State	Published - Apr 16 2019

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1016/j.celrep.2019.03.066

Cite this

Choi, H., Deng, J., Li, S., Silk, T., Dong, L., Brea, E. J., Houghton, S., Redmond, D., Zhong, H., Boiarsky, J., Akbay, E. A., Smith, P. D., Merghoub, T., Wong, K. K., & Wolchok, J. D. (2019). Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. Cell Reports, 27(3), 806-819.e5. https://doi.org/10.1016/j.celrep.2019.03.066

@article{ce2c28a6d64c4ebfbb325b3484ea93a0,

title = "Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer",

abstract = "KRAS mutant non-small-cell lung cancer (NSCLC) remains refractory to targeted therapeutics. Choi et al. show that pulsatile, rather than continuous, treatment with MEK inhibitors can maintain T cell activity better and prolong survival in mice with Kras mutant cancer. This effect is further enhanced when combined with CTLA-4 blockade.",

author = "Hyejin Choi and Jiehui Deng and Shuai Li and Tarik Silk and Lauren Dong and Brea, {Elliott J.} and Sean Houghton and David Redmond and Hong Zhong and Jonathan Boiarsky and Akbay, {Esra A.} and Smith, {Paul D.} and Taha Merghoub and Wong, {Kwok Kin} and Wolchok, {Jedd D.}",

note = "Publisher Copyright: {\textcopyright} 2019 The Authors",

year = "2019",

month = apr,

day = "16",

doi = "10.1016/j.celrep.2019.03.066",

language = "English (US)",

volume = "27",

pages = "806--819.e5",

journal = "Cell Reports",

issn = "2211-1247",

publisher = "Cell Press",

number = "3",

}

TY - JOUR

T1 - Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer

AU - Choi, Hyejin

AU - Deng, Jiehui

AU - Li, Shuai

AU - Silk, Tarik

AU - Dong, Lauren

AU - Brea, Elliott J.

AU - Houghton, Sean

AU - Redmond, David

AU - Zhong, Hong

AU - Boiarsky, Jonathan

AU - Akbay, Esra A.

AU - Smith, Paul D.

AU - Merghoub, Taha

AU - Wong, Kwok Kin

AU - Wolchok, Jedd D.

PY - 2019/4/16

Y1 - 2019/4/16

N2 - KRAS mutant non-small-cell lung cancer (NSCLC) remains refractory to targeted therapeutics. Choi et al. show that pulsatile, rather than continuous, treatment with MEK inhibitors can maintain T cell activity better and prolong survival in mice with Kras mutant cancer. This effect is further enhanced when combined with CTLA-4 blockade.

AB - KRAS mutant non-small-cell lung cancer (NSCLC) remains refractory to targeted therapeutics. Choi et al. show that pulsatile, rather than continuous, treatment with MEK inhibitors can maintain T cell activity better and prolong survival in mice with Kras mutant cancer. This effect is further enhanced when combined with CTLA-4 blockade.

UR - http://www.scopus.com/inward/record.url?scp=85064175042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064175042&partnerID=8YFLogxK

U2 - 10.1016/j.celrep.2019.03.066

DO - 10.1016/j.celrep.2019.03.066

M3 - Article

C2 - 30995478

AN - SCOPUS:85064175042

SN - 2211-1247

VL - 27

SP - 806-819.e5

JO - Cell Reports

JF - Cell Reports

IS - 3

ER -

Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this